Technologies for the surface modification of biomaterials

Biomaterials in Orthopedics

Volumn , Issue , 2003, Pages 93-148

  Anderson, Aron B ^a   Dallmier, Anthony W ^a   Chudzik, Stephen J ^a   Duran, Lise W ^a   Guire, Patrick E ^a   Hergenrother, Robert W ^a   Lodhi, Muhammad A ^a   Novak, Amy E ^a   Ofstead, Ronald F ^a   Wormuth, Klaus ^a  

^a SurModics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013946880     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (106)

1. March J. Advanced Organic Chemistry. 3rd Edition. New York: Wiley, 1985:216,1078.
2. Galardy RE, Craig LC, Jamieson JD, Printz MP. J. Biol. Chem 1974; 249:3510.
3. Swan DG, Hastings CA. U.S. Patent 5,414,075, 1995.
4. Nagaoka S, Akashi R. J. Bioactive Compatible Polymers 1990; 5:212.
5. Kallmes DF, McGraw JK, Evans AJ, Mathis JM, Hergenrother RW, Jensen ME, Cloft HJ, Lopes M, Dion JE. Am. J. Neuroradiol 1997; 18:1243-1251.
6. Park KD, Okano T, Nojiri C, Kim SW. J. Biomed. Mater. Res 1988; 22:977.
7. Rollason G, Sefton MV. J. Biomater. Sci. Polym Ed 1989; 1:31.
8. Hoffman AS, Horbett TA, Ratner BD. Ann. NY Acad. Sci 1977; 283:372.
9. Marchant RE, Johnson SD, Schneider BH, Agger MP, Anderson JM. J. Biomed. Mater. Res 1990; 24:1521.
10. Ip WF, Sefton MV. J. Biomed. Mater. Res 1991; 25:875.
11. Hsuie GH, Yang JM, Wu RL. J. Biomed. Mater. Res 1988; 22:405.
12. Mori Y, Nagaoka S, Takiuchi H, Noguchi N, Tanzawa H, Noishiki Y. Trans. Am. Soc. Artif. Intern. Organs 1982; 28:459.
13. Nojiri C, Okano T, Jacobs HA, Park KD, Mohammad SF, Olsen DB, Kim SW. J. Biomed. Mater. Res 1990; 24:1151.
14. Munro MS, Quattrone AJ, Ellsworth SR, Kulkarni P, Eberhardt RC. Trans. Am. Soc. Artif. Intern. Organs 1981; 27:499.
15. Eberhardt RC, Munro MS, Williams GB, Kulkarni PV, Shannon WA, Brink BE, Fry WJ. Artif. Organs 1987; 11:375.
16. Grasel TG, Pierce JA, Cooper SL. J. Biomed. Mater. Res 1987; 21:815.
17. Keogh JR, Velander FF, Eaton JW. J. Biomed. Mater. Res 1992; 26:441.
18. Hayward JA, Durrani AA, Shelton CJ, Lee DC, Chapman D. Biomaterials 1986; 7:126.
19. Jacobs HJ, Okano T, Kim SW. J. Biomed. Mater. Res 1989; 23:611.
20. Ito Y, Iguchi Y, Kashiwagi T, Imanishi Y. J. Biomed. Mater. Res 1991; 25:1347.
21. Okkema AZ, Visser SA, Cooper SL. J. Biomed. Mater. Res 1991; 25:1371.
22. Santerre JP, ten Hove P, VanderKamp NH, Brash JL. J. Biomed. Mater. Res 1992; 26:39.
23. Smith PK, Mallia AK, Hermanson GT. Anal. Biochem 1980; 109:466.
24. Sukavaneshvar S. In vitro assessment of device thrombosis and thromboembolism from roadmap to successful development and regulatory approval of medical devices with hemocompatible coatings workshop handbook, Scottsdale, AZ, 2001.
25. Stamm WE. Infections related to medical devices. Ann. Int. Med 1978; 89:764-769.
26. Stamm WE. Prevention of infections. Infections related to medical devices. Ann. Intern. Med 1978; 89:764-769.
27. Donelli G, Francolini I. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review. J. Chemotherapy 2001; 13:595-606.
28. Carson CC. Management of prosthesis infections in urologic surgery. Urol. Clin. North. Am 1999; 26:829-839.
29. Mulcahy JJ. Long-term experience with salvage of infected penile implants. J. Urol 2000; 163: 481-482.
30. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin. Infectious Diseases 2001; 33:1567-1572.
31. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin. Infectious Diseases 2001; 33:1387-1392.
32. Christensen GD, Simpson WA, Bisno AL, E.H. AL, Beachey AL. Infect. Immun 1983; 40:407-410.
33. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. J. Infect. Dis 1982; 146:487-496.
34. Oakes JA, Wood AJJ. Infections in surgery. N. Engl. J. Med 1986; 315:1129-1138.
35. Nelson CL. Environmental bacteriology in the unidirectional (horizontal) operating room. Arch. Surg 1979; 114:778-782.
36. Anwar H, Strap JL, Chen K, Costerton JW. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Antimicrobial Agents Chemother 1992; 36: 1208-1214.
37. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Ann. Rev. Microbiol 1995; 49:711-745.
38. McEldowney S, Fletcher M. J. Gen. Microbiol 1986; 132:513-523.
39. Pasmore M, Todd P, Smith S, Baker D, Silverstein J, Coons D, Bowman CN. Effects of ultrafiltration membrane surface properties on Pseudomonas aeruginosa biofilm initiation for the purpose of reducing biofouling. J. Mem. Sci 2001; 194:15-32.
40. Gristina AG. Science 1987; 237:1588-1595.
41. Darveau RP, Blake J, Seachord CL, Cosand WL, Cunningham MD, Cassiano-Clough L, Maloney G. J. Clin. Invest 1992; 90:447.
42. Zasloff M. Proc. Natl. Acad. Sci. USA 1987; 84:5449.
43. Giovannini MG, Poulter L, Gibson BW, Williams DH. Biochem. J 1987; 243:113-120.
44. Williams RW, Starman R, Taylor KMP, Gable K, Beeler T, Zasloff M, Covell D. Biochemistry 1990; 29:4490-4496.
45. Cannon M. Nature 1987; 328:478.
46. Gwadz RW, Kaslow D, Lee J, Maloy WL, Zasloff M, Miller LH. Infection and Immunity 1989; 57:2628-2633.
47. Soravia E, Martini G, Zasloff M. FEBS Lett 1988; 228:337-340.
48. Dankert J, Hogt AH, Feigen J. CRC Crit. Rev. Biocompat 1986; 2:219-301.
49. Peters G, Gray ED, Johnson GM. In: Bisno AL, Waldvogel FA, eds. Infections Associated with Indwelling Medical Devices. Washington, DC: American Society for Microbiology, 1989:61-74.
50. Zasloff M, Martin B, Chen HC. Proc. Natl. Acad. Sci. USA 1988; 85:910-913.
51. Ratner BD. The blood compatibility catastrophe. J. Biomed. Mater. Res 1993; 27:283-287.
52. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872-1878.
53. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J. Am. Coll. Cardiol 1994; 23:1234.
54. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Circulation 1994; 90:2070.
55. Hanson SR, Ratner BD. Testing of blood-materials interactions. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE, eds, Biomaterials Science, Academic Press. 1996:228-238.
56. Camenzind E, Kutryk MJB, Serruys PW. Use of locally delivered conventional drug therapies. Semin. Intervent. Cardiol 1996; 1:67.
57. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94:1690-1697.
58. Hårdhammar PA, van Beusekom HMM, Emanuelsson HU, Hofma SH, Albertson PA, Verdouw PD, Boersma E, Serruys PW, van der Giessen WJ. Reduction in thrombotic events with heparincoated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93:423.
59. Serruys PW. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med 1994; 331:489.
60. Hill RS, Cruise GM, Hager SR, Lamberti FV, Yu X, Garufis CL, Yu Y, Mundwiler KE, Cole JF, Hubbell JA, Hegre OD, Scharp DS. Ann NY Acad. Sci 1997; 831:332-343.
61. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992; 86:723.
62. Bauters C, Meurice T, Hamon M, McFadden E, Lablanche J-M, Bertrand ME. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc. Res 1996; 31:835.
63. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of Sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193.
64. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AGMR, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal proliferation by Sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104:2007-2011.
65. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med 2002; 346:1773-1780.
66. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas DG. Science 1991; 251:767-773.
67. Southern EM, Maskos U, Elder JK. Genomics 1992; 13:1008-1017.
68. Brown PO, Botstein D. Nature Genet 1999; 21:33-37.
69. Lipshutz RJ, Fodor SPA, Gingeras TR, Lockhart DJ. Nature Genet 1999; 21:20-24.
70. Eisen MB, Brown PO. Methods Enzymol 1999; 303:179-205.
71. Haab BB, Dunham MJ, Brown PO. Genome Biol, 2001.
72. Walter G, Büssow K, Cahill D, Lueking A, Lehrach H. Curr Opin Microbiol 2000; 3(3):2998-302.
73. MacBeath G, Schreiber S. Science 2000; 289:1761-1763.
74. Heng Z, Bilgin M, Bangham R, Hall D, Casamayor A. Science 2001; 293:2101-2105.
75. Lam KS, Renil M. Curr Opin Chem Biol 2002; 6(3):353-358.
76. Seeskin E. Drug Discovery Today, Spring 2002:43-47.
77. Xu CW. Genome Research 2002; 12(3):482-486.
78. Ziauddin J, Sabatini DM. Nature 2001; 411:107-110.
79. Wang D, Liu S, Trummer BJ, Deng C, Wang A. Nature Biotech 2002; 20:275-281.
80. Houseman BT, Mrksich M. Chem. Biol 2002; 9(4):443-454.
81. Andersen CL, Monni O, Wagner U, Kononen J, Barlund M. Am. J Pathol 2002; 161(1):73-79.
82. Skacel M, Skilton B, Pettay JD, Tubbs RR. Appl Immunohistochem Mol Morphol 2002; 10(2): 1-6.
83. Terris B, Bralet MP. Ann Pathol 2002; 22(1):69-72.
84. Shoemaker DD, Schadt EE, Armour CD, He YD, Garrett-Engele R. Nature 2001; 409:922-927.
85. Hacia JG, Brody LC, Chee MC, Fodor SP, Collins FS. Nature Genet 1996; 14:441-447.
86. Cutler DJ, Zwick ME, Carraquillo MM, Yohan CT, Tobin KP. Genome Res 2001; 11:1913-1925.
87. Chee M, Yang R, Hubbell E, Berno A, Huang XC. Science 1996; 277:610-614.
88. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. Proc Natl Acad Sci, USA 1996; 93:10614-10619.
89. DeRisi JL, Iyer V, Brown PO. Science 1997; 278:680-686.
90. Ewing B, Green P. Nature Genet 2000; 25:232-234.
91. International Genome Sequencing Consortium. Nature 2001; 409:860-921.
92. Butler JE, Ni L, Brown WR, Joshi KS, Chang J, Rosenberg B, Voss EW, Jr. Mol Immunol 1993; 30(13):1165-1175.
93. Lindroos K, Liljedahl U, Raito M, Syvanen A-C. Nucl Acids Res 2001; 29(13):e69.
94. Ramakrishnan R, Dorris D, Lublinsky A, Nguyen A, Domanus M. Nucl Acids Res 2002; 30(7): e30.
95. Lockhart DJ, Winzler EA. Nature 2000; 405:827-836.
96. Hughes TR, Mao M, Jones AR. Nature Biotech 2001; 19:342-347.
97. Means GE, Feeney RE. Biochemistry 1968; 7:2192-2201.
98. Charonis AS, Skubitz APN, Koliakos GG, Reger LA, Dege J, Vogel AM, Wohlhueter R, Furcht LT. J. Cell Biol 1988; 107:1253-1260.
99. Green LM, Reade JL, Ware CF. J. Immunol. Methods 1984; 70:257-268.
100. Koliakos GG, Kouzi-Koliakos K, Furcht LT, Reger LA, Tsilibary EC. J. Biol. Chem 1989; 264: 2313-2323.
101. Pierschbacher MD, Ruoslahti E. Nature 1984; 309:30-33.
102. Kirkham SM, Dangel ME. Ophth. Surg[(&&&)] 1991; 22:455-461.
103. Clapper DL, Hagen KM, Hupfer NM, Anderson JM, Guire PE. Trans. Soc. Biomater 1993; 16:42.
104. Shapiro PE. N. Engl. J. Med 2000; 343:230-238.
105. Cruise GM, Hegre OD, Lamberti FV, Hager SR, Hill R, Scharp DS, Hubbell JA. Cell Transplantation 1999; 8:293-306.
106. Cruise GM, Hegre OD, Scharp DS, Hubbell JA. Biotech. Bioeng 1998; 57:655-665.